Management of Immune Checkpoint Inhibitor-Related Diarrhea
Initial Assessment and Workup
- The National Comprehensive Cancer Network recommends ruling out infection immediately before initiating any antidiarrheal therapy, as this is the most critical first step 1, 2
- Obtain stool studies for enteropathogens and Clostridium difficile toxin in all patients with diarrhea 3
- Measure fecal lactoferrin or calprotectin as inflammatory markers; positive lactoferrin has 90% sensitivity for histologic inflammation and predicts need for aggressive therapy 2, 4
- Consider abdominal/pelvic CT with contrast for grade ≥2 symptoms 2
- Perform early endoscopy (colonoscopy or flexible sigmoidoscopy) within 7-14 days of symptom onset, especially if lactoferrin is positive, even with only grade 1 symptoms 2, 4, 5
Grade 1 Diarrhea Management
- The National Comprehensive Cancer Network recommends managing conservatively with hydration and considering holding immunotherapy 2, 6
- Provide oral rehydration and electrolyte replacement 1
- Loperamide may be used cautiously (maximum 16 mg/day) if infection is ruled out 2, 4
- Add mesalamine or cholestyramine if symptoms persist with negative lactoferrin 4, 6
Grade 2 Diarrhea Management
- Hold immunotherapy and initiate corticosteroids at 1 mg/kg/day prednisone equivalent unless diarrhea is transient 1, 7
- Start with oral prednisone 1 mg/kg/day (or budesonide 9 mg once daily if no bloody diarrhea) 7, 8
- Consider gastroenterology consultation 1
- Perform endoscopy to stratify risk based on endoscopic findings; presence of ulcers predicts steroid-refractory course in 88% of cases 1
Grade 3 Diarrhea Management
- Administer IV methylprednisolone 1-2 mg/kg/day and consider early biologics if high-risk endoscopic features or inadequate steroid response after 3 days 1, 9
- Use IV methylprednisolone especially if concern for upper GI inflammation 1, 9
- Add infliximab 5 mg/kg or vedolizumab if no improvement within 3 days of steroids or if colonic ulcers present on endoscopy 1, 9
Grade 4 Diarrhea Management
- Permanently discontinue immunotherapy, provide inpatient care, and administer IV methylprednisolone 1-2 mg/kg/day with early biologics 1, 9
- Give infliximab or vedolizumab if inadequate response to steroids after 3 days 1, 9
- Consider repeat colonoscopy if refractory to treatment 1, 9
Critical Timing Considerations
- Early endoscopy within 7 days reduces symptom duration from 47 to 19 days and steroid treatment duration from 74 to 49 days 2, 4, 5
- Endoscopy within 30 days reduces symptom recurrence from 50% to 21.8% 2, 4
Special Considerations and Pitfalls
- Never use infliximab in patients with concurrent hepatic immune-related adverse events; it is contraindicated 1, 9
- Vedolizumab is gut-specific and may preserve antitumor immunity better than infliximab 4, 6, 5
- Add Pneumocystis prophylaxis (trimethoprim/sulfamethoxazole 400 mg daily) when immunosuppression is prolonged 7, 8
- Fecal calprotectin ≤116 mg/g may serve as surrogate for endoscopic/histologic remission before resuming immunotherapy 1, 9
- PD-1/PD-L1 agents have lower flare risk upon resumption than CTLA-4 inhibitors 1, 9